The year 2025 has become a critical turning point for stem cell therapies transitioning from the laboratory to clinical applications. In January, China’s first stem cell therapy, Amimestrocel Injection, received conditional approval from the National Medical Products Administration (NMPA), marking the official entry of regenerative medicine into the commercialization phase. This innovative therapy for acute graft-versus-host disease (GVHD) not only filled a gap in the domestic stem cell drug market but also established a strategic partnership with Alibaba Health in June. Through full-channel distribution and the establishment of a digital traceability system, it completed the industrial cycle from approval to clinical implementation, truly enabling cutting-edge therapeutic technologies to reach patients.

With the deep integration of policy innovation and industrial practice, numerous measures for the transformation of biomedical technologies have been introduced, opening fast-track approval pathways for stem cell therapies and achieving breakthroughs in stem cell technology, clinical translation, and industrialization. Currently, several stem cell therapies for conditions such as knee osteoarthritis and chronic lung diseases have been successfully applied. Through a dual regulatory model of "technology + drug," a balance between clinical value and patient accessibility has been achieved. In the foreseeable future, stem cell drugs are expected to experience a surge in large-scale production capacity.

However, the quality challenges behind industrial prosperity are becoming increasingly prominent. How to ensure cell viability and batch consistency throughout the entire chain—from bioreactors to final infusion—while scaling up production has become a critical issue for industrial advancement. Among these challenges, the selection of packaging materials plays a decisive role in factors such as formulation cryopreservation, transportation, long-term cryopreservation sealing, temperature stability, and impact resistance. It is a key variable in ensuring cell viability and batch consistency from production to clinical infusion, as well as a crucial gateway for the stem cell industry to move from technological breakthroughs to commercial implementation. The importance of packaging material selection, as a bridge between production and clinical application, is often underestimated. This article will review the current landscape of packaging materials for stem cell therapies and analyze the key characteristics of ideal future solutions.

The packaging formats for globally marketed stem cell therapies are determined based on cell characteristics, route of administration, storage conditions, as well as convenience and safety in clinical use. According to industry practices and available product information, the main packaging formats primarily include the following three types:

Cell Cryopreservation Bags

(Image: Commercially available stem cell therapy packaged in cell cryopreservation bags. Source: Internet)

Cell cryopreservation bags are one of the most mainstream final packaging formats for cell therapies, particularly for large-scale, commercially produced allogeneic stem cell drugs.

Advantages:
Clinical convenience: Can be quickly connected to a patient’s infusion system for intravenous administration.
Support for large-volume filling: Meets therapeutic dose requirements, with capacities easily reaching 50 mL, 100 mL, or even 500 mL.
Cryo-tolerance: Maintains physical stability at -196°C in liquid nitrogen, ensuring safety during long-term storage.

Clinical convenience: Can be quickly connected to a patient’s infusion system for intravenous administration.

Compatibility with automation: When paired with the 3D FloTrix vivaPACK PRO Cryobag Filling, it enables large-scale automated production. The filling process can be fully closed, reducing contamination risks.

Disadvantages and Challenges:
Despite their advantages, cryopreservation bags are not a universal solution. Their applicable scenarios and limitations must be clearly understood. The most critical challenge in scaling up production lies in the amplification of cryopreservation processes. Commercial production requires simultaneous and consistent processing of hundreds or even thousands of bags, presenting significant physical and engineering challenges. Cell viability and functionality highly depend on the cooling rate during cryopreservation. Rates that are too fast (leading to ice crystal formation) or too slow (causing cell dehydration damage) can result in cell death.

(Image: Schematic diagram of a controlled-rate freezer. Source: Internet)

Currently, the largest commercially available freezers typically have capacities of 45–50 L, accommodating 90 bags of 50 mL or 24 bags of 250–500 mL. Cryopreserving 10 billion cells in 100–200 bags requires at least 1–2 controlled-rate freezers. Scaling up to commercial production involving thousands of bags would require additional instruments or custom-built larger freezers, leading to limited production capacity, high costs, complex processes, and challenges in ensuring consistency.

Pre-Filled Syringes

(Image: Commercially available stem cell therapy packaged in pre-filled syringes. Source: Internet)

Pre-filled syringes are widely used in the biopharmaceutical industry for products such as vaccines and antibodies. In the cell therapy field, their application is primarily focused on autologous stem cell drugs. They offer convenience in administration by reducing operational steps during preparation and injection. However, while user-friendly, their design is not suitable for the long-term ultra-low-temperature stability required for large-scale, commercially produced allogeneic stem cell drugs. Thus, they are more suitable for fresh cell formulations.

COP Vials

(Image: Commercially available stem cell therapy packaged in COP vials. Source: Internet)

COP (cyclic olefin polymer) vials are currently the most widely used final packaging format for cell therapies, particularly for large-scale, commercially produced allogeneic stem cell drugs.

Key Advantages:

Excellent temperature resistance: Adapts to various storage conditions.
High-temperature tolerance: Withstands sterilization at temperatures up to 163°C.
Ultra-low-temperature tolerance: Remains stable at -80°C and in liquid nitrogen (-196°C), making it suitable for biologics requiring deep cryopreservation.

The thermal expansion coefficient is matched with rubber stoppers, reducing the risk of breakage during freeze-thaw cycles and ensuring container integrity.

(Image: Schematic diagram of rubber stoppers and aluminum caps. Source: Internet)

Stable and reliable sealing ensures formulation stability:

COP vials utilize a combination of rubber stoppers and aluminum caps, offering significant advantages in sealing. The elastic material of the rubber stopper tightly fits the vial opening, forming a reliable primary barrier that effectively prevents gas exchange and microbial ingress. The aluminum cap provides rigid fixation through mechanical compression, ensuring the stopper remains securely in place. The combination of both elements achieves a dual-seal protection.

The rubber stopper maintains good elasticity at low temperatures, unlike plastic caps which can become brittle and crack. It cushions the volumetric expansion of the formulation during freezing, while the aluminum cap provides necessary mechanical support to prevent vial breakage due to internal pressure changes. This makes COP vials particularly suitable for stem cell drugs requiring deep cryopreservation, effectively avoiding container integrity issues during freeze-thaw cycles.

Facilitates automated filling, unlocking large-scale production capacity :
COP vials possess fixed, standardized dimensions and outstanding rigidity, allowing them to be conveyed and gripped by equipment. Compared to cryopreservation bags, which are soft, easily deformed, and non-standardized, COP vials are more readily integrated into automated production lines.

Their superior rigidity further allows direct cryopreservation after filling without the requirement for degassing.

Excellent compatibility with controlled-rate freezing ensures cell quality and batch-to-batch consistency:
COP vials can be tightly inserted into standardized cryopreservation racks, enabling high-density, three-dimensional storage. A single large controlled-rate freezer can process tens of thousands of vials in a single run.

The regular, rigid vial walls and consistent liquid volume ensure that cold air circulates evenly and predictably between vials. Vials positioned in different location within the same cryopreservation rack experience highly consistent cooling profiles, guaranteeing high cell production quality and intra-batch uniformity.

As living cell products, stem cell drugs demand extremely high standards of sterility, operational timing, and consistency during filling. In our research on packaging formats for stem cell therapies, COP vials demonstrate significant advantages in commercial-scale production compared with other packaging formats, particularly in the two core stages of automated filling and formulation cryopreservation .

The commercial success of stem cell therapeutics is far more than a simple scale-up of laboratory techniques. It fundamentally depends on the establishment of an efficient, stable, controllable, and compliant large-scale formulation production and filling process. As a pioneer in cell therapy process development and a provider of comprehensive solutions, CytoNiche is set to launch the 3D FloTrix™ vivaVIAL filling system for COP vial formulation filling to address large-scale cell formulation filling needs. Stay tuned for upcoming product launch information.

(Image: 3D FloTrix™ vivaMIX intelligent cell mixing module and 3D FloTrix™ vivaVIAL filling system)